The company, launched with help from ex-Novartis executives, is targeting glutamate signaling in the brain to help treat ...

BEIJING, March 24 (Xinhua) -- Chinese Vice President Han Zheng met with Swire Pacific Limited chairman Merlin Swire, and Novartis CEO Vas Narasimhan on Monday in Beijing, who are here for the China ...

Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...

More and more people are talking about Novartis over the last few weeks. Is it worth buying the Pharmaceutical stock at a price of $112.13? Only time will tell. The information below will give you a ...

Global drugmaker Novartis will lay off 427 employees who report to the company's East Hanover headquarters this spring and ...

The pharma is spending $2.5 billion on an R&D center in Beijing. Elsewhere, Adaptimmune warned it could run out of cash and Pfizer sold its remaining stake in Haleon.

Pharmaceutical company Novartis is laying off more than 400 US employees who report to its East Hanover facility as part of a ...

Novartis was announced as an official partner of this year’s Eurovision competition last fall, after the song entry from ...

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

Alnylam Pharmaceuticals, Inc.’s ALNY share price has surged by 11.75%, which has investors questioning if this is right time ...

AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...

To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as ...